Livzon Pharmaceutical Group Inc.
000513
Clasificación en acciones
#4688
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
Precio por acción
$3.90
Capitalización bursátil
$3.17B
Cambio (1 día)
-3.49%
Cambio (1 año)
-25.88%
País
CN
Comercio Livzon Pharmaceutical Group Inc. (000513)
Categoría
Healthcare
Ganancias de Livzon Pharmaceutical Group Inc. (000513)
Ganancias en Jun 2026 TTM: $353.39M
Secondo gli ultimi rapporti finanziari di Livzon Pharmaceutical Group Inc., gli utili attuali della società sono $353.39M. Nel 2024, la società ha registrato un utile di $384.45M, un aumento con respecto a agli utili del 2023, che erano di $336.60M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Livzon Pharmaceutical Group Inc. desde 2001 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $353.39M | -13.61% |
| 2025 | $409.07M | 6.40% |
| 2024 | $384.45M | 14.22% |
| 2023 | $336.60M | -0.37% |
| 2022 | $337.86M | -4.38% |
| 2021 | $353.32M | -7.28% |
| 2020 | $381.07M | 53.60% |
| 2019 | $248.09M | 20.46% |
| 2018 | $205.95M | -76.59% |
| 2017 | $879.92M | 507.84% |
| 2016 | $144.76M | 16.35% |
| 2015 | $124.42M | 18.19% |
| 2014 | $105.27M | 1.52% |
| 2013 | $103.69M | 15.39% |
| 2012 | $89.85M | 22.30% |
| 2011 | $73.47M | -9.13% |
| 2010 | $80.85M | -6.35% |
| 2009 | $86.33M | 457.58% |
| 2008 | $15.48M | -81.76% |
| 2007 | $84.91M | 200.91% |
| 2006 | $28.22M | 72.44% |
| 2005 | $16.36M | -12.46% |
| 2004 | $18.69M | -1.91% |
| 2003 | $19.06M | 40.37% |
| 2002 | $13.58M | 11.75% |
| 2001 | $12.15M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $3.62B | 923.75% |
DE
|
|
| $3.40B | 863.51% |
DE
|
|
| $1.72B | 387.73% |
JP
|
|
| $930.30M | 163.25% |
CH
|
|
| $1.69B | 378.97% |
IN
|
